Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea – Pharmaceutical Technology
OSA is usually treated with a mask worn during sleep, called a continuous positive airway pressure (CPAP) machine. Credit: Kateryna Mostova via Shutterstock. Eli Lilly’s
December 25, 2024